<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02644915</url>
  </required_header>
  <id_info>
    <org_study_id>zxy</org_study_id>
    <nct_id>NCT02644915</nct_id>
  </id_info>
  <brief_title>Edaravone on the Ischemia-Reperfusion(I/R) Injury in Kidney Transplantation Patients</brief_title>
  <acronym>I/R</acronym>
  <official_title>Effect of Edaravone on the Ischemia-Reperfusion(I/R) Injury in Kidney Transplantation Patients: A Single-Center, Double-Blinded, Randomised Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xijing Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>First Affiliated Hospital Xi'an Jiaotong University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Xijing Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Ischemia-reperfusion (I/R) injury is a prominent cause of delayed graft function(DGF) after
      kidney transplantation. Reactive oxygen species play a crucial role in I/R injury. Edaravone
      is a synthetic radical scavenger that has been used in acute stroke. Some animal experiments
      have revealed its beneficial effects against I/R injury, our goal is therefore to investigate
      the effectiveness of a recipient pretreatment with Edaravone at reducing the occurrence of
      DGF after kidney transplantation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participants will be randomly assigned, in a 1:1 ratio, to receive Edaravone or control (0.9
      %Sodium Chloride Solution,0.9%NaCl). The randomization sequence will be computer-generated,
      and randomization will be performed in blocks and will be stratified according to
      participating center.Edaravone and 0.9 %NaCl solution will be treated at 10 minutes before
      kidney reperfusion, ending in 30 minutes. The number of dialysis and the serum creatinine
      level within the first week after the transplantation will be recorded. The participation of
      each patient is scheduled for 1 month.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>March 2016</start_date>
  <completion_date type="Anticipated">October 2016</completion_date>
  <primary_completion_date type="Anticipated">September 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of DGF(postoperative complication after kidney transplantation)（%）</measure>
    <time_frame>in the first week after the kidney transplantation</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>serum creatinine value (umoI/L)</measure>
    <time_frame>within the first week</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>average daily urinary volume（ml）</measure>
    <time_frame>within the first week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital stays after operation(d)</measure>
    <time_frame>Participants will be followed for the duration of hospital stay, an expected average of 2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>graft survival</measure>
    <time_frame>within 30 days after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>other postoperative complication:acute rejection episodes、thrombosis、infections</measure>
    <time_frame>within 30 days after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Content of Malondialdehyde（mol/m l）in the blood</measure>
    <time_frame>before transplantation and 1, 2, 3 days after transplantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Content of Superoxide dismutase（U /m l) in the blood</measure>
    <time_frame>before transplantation and 1, 2, 3 days after transplantation</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Kidney Transplantation</condition>
  <arm_group>
    <arm_group_label>study group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Edaravone 30mg dissolved in 0.9%NaCl 100ml will be treated at 10 minutes before kidney reperfusion, ending in 30 minutes.
Standard anaesthesia and standard cure are given for all patients. During the operation we maintain the target blood pressure by keeping Central Venous Pressure(CVP)&gt; 6 mmHg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>100ml 0.9%%NaCl solution,but without edaravone, will be treated at 10 minutes before kidney reperfusion, ending in 30 minutes.
Standard anaesthesia and standard cure are given for all patients. During the operation we maintain the target blood pressure by keeping Central Venous Pressure(CVP)&gt; 6 mmHg.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Edaravone</intervention_name>
    <description>Edaravone 30mg dissolved in 0.9%NaCl 100ml will be treated at 10 minutes before kidney reperfusion , ending in 30 minutes.The number of dialysis and the serum creatinine level within the first week after the transplantation will be recorded.The participation of each patient is scheduled for 1 month.</description>
    <arm_group_label>study group</arm_group_label>
    <other_name>Edaravone Injection</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.9%%NaCl solution</intervention_name>
    <description>100ml 0.9%%NaCl solution,but without edaravone ,will be treated at 10 minutes before kidney reperfusion , ending in 30 minutes.
Standard anaesthesia and standard cure are given for all patients. During the operation we maintain the target blood pressure by keeping Central Venous Pressure(CVP)&gt; 6 mmHg</description>
    <arm_group_label>control group</arm_group_label>
    <other_name>normal saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. ASAⅡ-Ⅲ,elective operation patients with end-stage renal disease

          2. Age 18yrs-55yrs for donors and the recipients

          3. patients under hemodialysis

          4. no other severe complications history for the donors and recipients

          5. the first kidney transplant recipients

          6. patients with written informed consent

        Exclusion Criteria:

          1. ASA Ⅳ

          2. a second renal transplant,a multiorgan transplant or a dual kidney transplant

          3. having severe comorbidity history,for example,severe cardiac dysfunction

          4. cold ischemia time&gt;24h or warm ischemia time&gt;45min

          5. variation of blood vessel ，operation time more than 2 hours

          6. bleeding volume in operation&gt;500ml and need for blood transfusion

          7. participate in the other clinical trial 3 months before the enrollment

          8. no suitable to participate in this experiment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Qiang Wang</last_name>
    <role>Study Chair</role>
    <affiliation>Xijing Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xiao-ying Zhao</last_name>
    <phone>13513616985</phone>
    <email>zhaoxy06@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Qiang Wang</last_name>
    <phone>86-29-84775343</phone>
    <email>wangqiang@fmmu.edu.cn</email>
  </overall_contact_backup>
  <reference>
    <citation>Zhang L, Wang F, Wang L, Wang W, Liu B, Liu J, Chen M, He Q, Liao Y, Yu X, Chen N, Zhang JE, Hu Z, Liu F, Hong D, Ma L, Liu H, Zhou X, Chen J, Pan L, Chen W, Wang W, Li X, Wang H. Prevalence of chronic kidney disease in China: a cross-sectional survey. Lancet. 2012 Mar 3;379(9818):815-22. doi: 10.1016/S0140-6736(12)60033-6. Erratum in: Lancet. 2012 Aug 18;380(9842):650.</citation>
    <PMID>22386035</PMID>
  </reference>
  <reference>
    <citation>Shah VR, Butala BP, Parikh GP, Vora KS, Parikh BK, Modi MP, Bhosale GP, Mehta T. Combined epidural and general anesthesia for paediatric renal transplantation-a single center experience. Transplant Proc. 2008 Dec;40(10):3451-4. doi: 10.1016/j.transproceed.2008.06.065.</citation>
    <PMID>19100411</PMID>
  </reference>
  <reference>
    <citation>Kontodimopoulos N, Niakas D. Overcoming inherent problems of preference-based techniques for measuring health benefits: an empirical study in the context of kidney transplantation. BMC Health Serv Res. 2006 Jan 14;6:3.</citation>
    <PMID>16412242</PMID>
  </reference>
  <reference>
    <citation>Ibrahim S, Jacobs F, Zukin Y, Enriquez D, Holt D, Baldwin W 3rd, Sanfilippo F, Ratner LE. Immunohistochemical manifestations of unilateral kidney ischemia. Clin Transplant. 1996 Dec;10(6 Pt 2):646-52.</citation>
    <PMID>8996759</PMID>
  </reference>
  <reference>
    <citation>Ojo AO, Wolfe RA, Held PJ, Port FK, Schmouder RL. Delayed graft function: risk factors and implications for renal allograft survival. Transplantation. 1997 Apr 15;63(7):968-74.</citation>
    <PMID>9112349</PMID>
  </reference>
  <reference>
    <citation>Perico N, Cattaneo D, Sayegh MH, Remuzzi G. Delayed graft function in kidney transplantation. Lancet. 2004 Nov 13-19;364(9447):1814-27. Review.</citation>
    <PMID>15541456</PMID>
  </reference>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 10, 2015</study_first_submitted>
  <study_first_submitted_qc>December 30, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 1, 2016</study_first_posted>
  <last_update_submitted>December 30, 2015</last_update_submitted>
  <last_update_submitted_qc>December 30, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 1, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Xijing Hospital</investigator_affiliation>
    <investigator_full_name>wangqiang</investigator_full_name>
    <investigator_title>professor</investigator_title>
  </responsible_party>
  <keyword>ischemia-reperfusion(I/R) injury</keyword>
  <keyword>Edaravone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Phenylmethylpyrazolone</mesh_term>
    <mesh_term>Antipyrine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

